TICKERNERD
Menu
REPLREPLHealthcare · Biotechnology

REPL Stock Forecast: Replimune Group, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$15
−1.45% on the day

The 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $20 — +30.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
34 / 100
Median analyst target
$20
Analysts covering
8
Total return, dividends reinvested
1W
+24.1%
1M
+51.7%
YTD
+54.0%
1Y
+179.8%
From 52W high
−1.8%
From 52W low
+780.6%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REPL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
71
Value
69
Growth
54
Momentum
50
Volatility
49
Size
43
Revisions
34
Quality
33
Issuance
12

Accruals (71): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

REPL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26REPLHigh $24Median $20Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $14Median $20High $24

The green dot is the last close — the median target sits +30.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026JP MorganMaintainsOverweight$17 → $20
7 Aug 2026WedbushUpgradeOutperform$12 → $19
4 Aug 2026Leerink PartnersUpgradeOutperform$11 → $17
31 July 2026Cantor FitzgeraldUpgradeOverweight—
31 July 2026WedbushMaintainsNeutral$9.00 → $12
30 June 2026WedbushMaintainsNeutral$6.00 → $9.00
30 June 2026WedbushMaintainsNeutral—
1 June 2026WedbushMaintainsNeutral—
13 Apr 2026Cantor FitzgeraldDowngradeNeutral—
13 Apr 2026HC Wainwright & Co.DowngradeSell—
13 Apr 2026JefferiesDowngradeHold—
13 Apr 2026JP MorganDowngradeUnderweight—
13 Apr 2026Leerink PartnersDowngradeMarket Perform—
13 Apr 2026WedbushDowngradeNeutral—
5 Feb 2026Piper SandlerMaintainsOverweight—
4 Feb 2026WedbushMaintainsOutperform—
3 Nov 2025BMO CapitalUpgradeMarket Perform—
27 Oct 2025HC Wainwright & Co.UpgradeBuy—
20 Oct 2025JP MorganUpgradeNeutral—
20 Oct 2025Leerink PartnersUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REPL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

REPL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Replimune Group, Inc. (REPL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.4×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
7.5×

Cheaper than 15% of US stocks

EV / EBITDA
−3.8×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−188.9%

Higher than 7% of US stocks

Return on assets
−94.4%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

REPL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REPLReplimune Group, Inc.$1.4B
34
LTGOLatigo Biotherapeutics, Inc.$1.2B
0
CRVSCorvus Pharmaceuticals, Inc.$1.2B
55
ANROAlto Neuroscience, Inc.$1.2B
55
CGEMCullinan Therapeutics, Inc.$1.3B
71
EYPTEyePoint, Inc.$1.2B
22
MGTXMeiragtx Holdings plc$1.3B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REPL news & analysis

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 14 Aug 2026negative

Glancy Prongay Wolke & Rotter LLP reminded investors of the October 5, 2026 deadline to file a lead plaintiff motion in a securities fraud class action against Replimune Group, Inc. The lawsuit covers investors who purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026.

Why it matters — REPL watchers would care because a securities fraud class action has been filed against the company covering a defined class period, with a lead plaintiff filing deadline approaching.

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Replimune Group reported fiscal first quarter 2027 financial results and a corporate update. The company announced FDA accelerated approval of TUDRIQEV™ in combination with nivolumab, with a commercial launch planned within 60 days, the appointment of Michelle DiNapoli as Chief Commercial Officer, and a recently completed financing that extends its cash runway to support the commercial launch and confirmatory trial.

Why it matters — REPL watchers would care because the FDA approval, new commercial leadership, and extended cash runway mark significant progress toward the company's first commercial product launch.

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026

GlobeNewsWire · 14 Aug 2026negative

Kirby McInerney LLP has filed a securities fraud class action lawsuit on behalf of investors who purchased Replimune Group, Inc. securities, and is reminding affected investors to contact the firm by October 5, 2026 to discuss their rights or interests in the case.

Why it matters — A REPL watcher would care because the securities fraud lawsuit indicates legal and regulatory risk facing the company and its shareholders.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

PRNewsWire · 13 Aug 2026negative

A securities class action has been filed against Replimune Group, Inc. on behalf of shareholders who purchased between October 20, 2025 and April 10, 2026, with a lead plaintiff deadline of October 5, 2026. The lawsuit follows the FDA's April 2026 rejection of Replimune's RP1 resubmission, which cited unresolved study design concerns, causing REPL shares to drop to $1.70.

Why it matters — REPL watchers would care because the class action and FDA rejection raise significant regulatory and legal concerns surrounding the company's lead product candidate RP1, which has already had a severe impact on the stock price.

FAQ

Frequently asked questions about REPL stock

What is the REPL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REPL stock a buy right now?

Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 34 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REPL?

As at 15 Aug 2026, Replimune Group, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (71 of 100).

Will REPL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +30.3% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 34 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REPL stock forecast for 2030?

No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.

How has REPL stock performed over the past year?

Replimune Group, Inc. returned +179.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Replimune Group, Inc. do?

Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment.

What is the latest news on REPL?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit". Glancy Prongay Wolke & Rotter LLP reminded investors of the October 5, 2026 deadline to file a lead plaintiff motion in a securities fraud class action against Replimune Group, Inc. The lawsuit covers investors who purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026.

Company

About Replimune Group, Inc.

Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment. Its proprietary product candidates harness oncolytic viruses to selectively replicate in and destroy tumor cells while activating the patient's immune system against cancer. The lead candidate, RP1, is a modified herpes simplex virus type 1 (HSV-1) engineered to express GALV-GP R(-) and human GM-CSF, targeting a broad spectrum of solid tumors. Complementing this, RP2 incorporates an anti-CTLA-4 antibody-like protein to counteract immune inhibition, enhancing T-cell responses. RP3 further advances this platform by expressing additional immune-activating proteins to stimulate T cells more potently. Replimune Group Inc. operates within the oncology sector, focusing on innovative immunotherapies that aim to transform cancer care through precise viral mechanisms. Founded in 2015 and headquartered in Woburn, Massachusetts, the company plays a key role in advancing next-generation biologics in the biopharmaceutical market.

CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com